FDA approves dispersible dolutegravir/abacavir/3TC for children
2 May 2022. Related: Antiretrovirals.
On 30 March 2022, the US FDA approved a single tablet regimen of dolutegravir/abacavir/3TC in a dispersible formulation for children weighing 10 kgs to 25 kgs.
This will provide a simpler and easier to take option for children living with HIV.
Reference
ViiV Healthcare. ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV. (30 March 2022).
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv